BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccine
BioNTech has axed a Phase 2 trial of its personalized mRNA cancer vaccine just a week after Moderna and Merck had breakout success for their own approach in a much different cancer setting. BioNTech said ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.